Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408531 · ClinicalTrials.gov registry record · NA
LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
A NA study, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
NCT07408531: Recruiting NA study, sponsored by University of Illinois at Chicago.
NCT07408531 is a NA study that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 2,500 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07408531, a NA study, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.
Primary Outcome
To assess eligibility classification using USPSTF versus expanded criteria (Potter and American Cancer Society) and Sybil AI lung cancer risk scores calculated for all participants, including overlap between eligibility groups.
Interventions
- DIAGNOSTIC_TEST Sybil Artificial Intelligence (AI) screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2038-02 |
| Phase | NA |
What NCT07408531 shows while recruiting
NCT07408531 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 1 intervention - of which Sybil Artificial Intelligence (AI) screening is the first listed.
NCT07408531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07408531 about?
NCT07408531 is a clinical study titled "LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)". This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (b...
What is the current status of trial NCT07408531?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2026-03-12. Estimated completion is 2038-02.
What interventions are being tested in trial NCT07408531?
The interventions under investigation include: Sybil Artificial Intelligence (AI) screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07408531?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07408531's enrollment target sits among peer trials
2,500 44th of 2000 higher than 1,956 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI